MedTrace Logo

Febuxostat Versus Allopurinol on Hepatic Steatosis in MAFLD Patients

NCT05474560 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2023-08-01

No results posted yet for this study

Summary

Metabolic associated fatty liver disease (MAFLD) is the most common and harmful chronic liver disease, and it is increasingly diagnosed in many developed and developing countries.

Previous studies suggested a significant association between hyperuricemia and MAFLD and that hyperuricemia plays a causal role in the development of MAFLD.

Xanthine oxidase is a key enzyme in uric acid metabolism, and It thus can be considered as is a therapeutic target for MAFLD, so long-term urate-lowering therapy may play a role in amelioration of MAFLD by controlling uric acid levels. So, this study is conducted to assess the effect of controlling hyperuricemia using different xanthine oxidase inhibitors on amelioration of MAFLD.

Conditions

  • Non-Alcoholic Fatty Liver Disease
  • Hyperuricemia

Interventions

DRUG

Allopurinol (100 mg/day) plus lifestyle intervention

participants accept allopurinol treatment (100 mg, once a day, orally). Behavioral: lifestyle intervention According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).

DRUG

Febuxostat 40 mg plus lifestyle intervention

participants accept Febuxostat treatment (100 mg, once a day, orally). Behavioral: lifestyle intervention According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).

BEHAVIORAL

Life style intervention

According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Sarah Ma Zaki, Ass.Prof. · Ain Shams University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2023-01-28
Completion
2023-01-28

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05474560 on ClinicalTrials.gov